| 1 |
Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90.
DOI
|
| 2 |
Park JS, Lim JY, Park SK, et al. Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat 2011;43:236-243.
DOI
|
| 3 |
Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer- -a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306-2314.
DOI
|
| 4 |
Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-1518.
DOI
|
| 5 |
Ford H, Marshall A, Wadsley J, et al. COUGAR-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma [abstract]. J Clin Oncol 2013;31(4 Suppl):LBA4.
DOI
|
| 6 |
Fuchs CS, Tomasek J, Cho JY, et al. REGARD: a phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine- containing combination therapy [abstract]. J Clin Oncol 2013;31(4 Suppl):LBA5.
DOI
|
| 7 |
Lee JH, Kim SH, Oh SY, et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. Korean J Intern Med 2013;28:314-321.
DOI
|
| 8 |
Cho JY, Lim JY, Cheong JH, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 2011;17:1850-1857.
DOI
|
| 9 |
Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
DOI
|
| 10 |
Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
DOI
|
webmaster
